Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Report

Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment (Chemotherapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-1-68038-703-2
Number of Report Pages: 100
Format: PDF, Horizon Databook

Historical Range: 2018 - 2022
Forecast Period: 2024 - 2030
Industry: Healthcare

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
  1.2. Market Definitions
  1.3. Research Methodology
1.3.1. Information Procurement
  1.3.2. Information or Data Analysis
  1.3.3. Market Formulation & Data Visualization
  1.3.4. Data Validation & Publishing
  1.4. Research Scope and Assumptions
  1.4.1. List of Data Sources
Chapter 2. Executive Summary
  2.1. Market Outlook
  2.2. Segment Outlook
  2.3. Competitive Insights
Chapter 3. Non-small cell lung cancer therapeutics market Variables, Trends, & Scope
  3.1. Market Introduction/Lineage Outlook
  3.2. Market Size and Growth Prospects (USD Million)
  3.3. Market Dynamics
  3.3.1. Market Drivers Analysis
  3.3.2. Market Restraints Analysis
  3.4. Non-small Cell Lung Cancer Therapeutics Market Analysis Tools
  3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
  3.4.1.2. Bargaining power of the buyers
  3.4.1.3. Threats of substitution
  3.4.1.4. Threats from new entrants
  3.4.1.5. Competitive rivalry
  3.4.2. PESTEL Analysis
  3.4.2.1. Political landscape
  3.4.2.2. Economic and Social landscape
  3.4.2.3. Technological landscape
  3.4.2.4. Environmental landscape
  3.4.2.5. Legal landscape
Chapter 4. Non-small Cell Lung Cancer Therapeutics Market: Type Estimates & Trend Analysis
  4.1. Segment Dashboard
  4.2. Non-small Cell Lung Cancer Therapeutics Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  4.3. Squamous Cell Carcinoma
  4.3.1. Squamous Cell Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.4. Large Cell Carcinoma
  4.5. Large Cell Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.6. Adenocarcinoma
  4.6.1. Adenocarcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.7. Others
  4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Non-small Cell Lung Cancer Therapeutics Market: Treatment Estimates & Trend Analysis
  5.1. Segment Dashboard
  5.2. Non-small Cell Lung Cancer Therapeutics Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
  5.3. Chemotherapy
  5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.4. Targeted Therapy
  5.4.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.5. Immunotherapy
  5.5.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Estimates & Trend Analysis
  6.1. Segment Dashboard
  6.2. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  6.3. Hospital Pharmacy
  6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.4. Drug Store and Retail Pharmacy
  6.4.1. Drug Store and Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5. Online Pharmacy
  6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Non-small Cell Lung Cancer Therapeutics Market: Regional Estimates & Trend Analysis
  7.1. Non-small Cell Lung Cancer Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
  7.2. North America
  7.2.1. North America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.2.2. U.S.
  7.2.2.1. U.S. Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.2.3. Canada
  7.2.3.1. Canada Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.2.4. Mexico
  7.2.4.1. Mexico Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.3. Europe
  7.3.1. Europe Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.3.2. UK
  7.3.2.1. UK Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.3.3. Germany
  7.3.3.1. Germany Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.3.4. France
  7.3.4.1. France Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.3.5. Italy
  7.3.5.1. Italy Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.3.6. Spain
  7.3.6.1. Spain Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.3.7. Denmark
  7.3.7.1. Denmark Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.3.8. Sweden
  7.3.8.1. Sweden Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.3.9. Norway
  7.3.9.1. Norway Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.4. Asia Pacific
  7.4.1. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.4.2. Japan
  7.4.2.1. Japan Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.4.3. China
  7.4.3.1. China Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.4.4. India
  7.4.4.1. India Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.4.5. Australia
  7.4.5.1. Australia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.4.6. South Korea
  7.4.6.1. South Korea Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.4.7. Thailand
  7.4.7.1. Thailand Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.5. Latin America
  7.5.1. Latin America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.5.2. Brazil
  7.5.2.1. Brazil Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.5.3. Argentina
  7.5.3.1. Argentina Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.6. Middle East and Africa
  7.6.1. Middle East and Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.6.2. South Africa
  7.6.2.1. South Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.6.3. Saudi Arabia
  7.6.3.1. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.6.4. UAE
  7.6.4.1. UAE Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  7.6.5. Kuwait
  7.6.5.1. Kuwait Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
  8.1. Recent Developments & Impact Analysis by Key Market Participants
  8.2. Company Categorization
  8.3. Company Heat Map Analysis
  8.4. Company Profiles
  8.4.1. F. Hoffmann-La Roche Ltd
  8.4.1.1. Participant’s Overview
  8.4.1.2. Financial Performance
  8.4.1.3. Product Benchmarking
  8.4.1.4. Recent Developments/ Strategic Initiatives
  8.4.2. Mylan N.V.
  8.4.2.1. Participant’s Overview
  8.4.2.2. Financial Performance
  8.4.2.3. Product Benchmarking
  8.4.2.4. Recent Developments/ Strategic Initiatives
  8.4.3. Teva Pharmaceutical Industries Ltd.
  8.4.3.1. Participant’s Overview
  8.4.3.2. Financial Performance
  8.4.3.3. Product Benchmarking
  8.4.3.4. Recent Developments/ Strategic Initiatives
  8.4.4. Sanofi
  8.4.4.1. Participant’s Overview
  8.4.4.2. Financial Performance
  8.4.4.3. Product Benchmarking
  8.4.4.4. Recent Developments/ Strategic Initiatives
  8.4.5. Pfizer Inc.
  8.4.5.1. Participant’s Overview
  8.4.5.2. Financial Performance
  8.4.5.3. Product Benchmarking
  8.4.5.4. Recent Developments/ Strategic Initiatives
  8.4.6. GSK plc
  8.4.6.1. Participant’s Overview
  8.4.6.2. Financial Performance
  8.4.6.3. Product Benchmarking
  8.4.6.4. Recent Developments/ Strategic Initiatives
  8.4.7. Novartis AG
  8.4.7.1. Participant’s Overview
  8.4.7.2. Financial Performance
  8.4.7.3. Product Benchmarking
  8.4.7.4. Recent Developments/ Strategic Initiatives
  8.4.8. Bayer AG
  8.4.8.1. Participant’s Overview
  8.4.8.2. Financial Performance
  8.4.8.3. Product Benchmarking
  8.4.8.4. Recent Developments/ Strategic Initiatives
  8.4.9. Eli Lilly and Company
  8.4.9.1. Participant’s Overview
  8.4.9.2. Financial Performance
  8.4.9.3. Product Benchmarking
  8.4.9.4. Recent Developments/ Strategic Initiatives
  8.4.10. Merck & Co., Inc
  8.4.10.1. Participant’s Overview
  8.4.10.2. Financial Performance
  8.4.10.3. Product Benchmarking
  8.4.10.4. Recent Developments/ Strategic Initiatives

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.